John Manllo Dieck, MD
Internal Medicine · McAllen, TXNPI 1578855680
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by CSL Behring at 42.8% of the total. Reporting peaked in 2024 at $2,920 and has fallen 78.0% since, to $641 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Vifor Pharma, Inc.$1K
- Amgen$570
- Fresenius USA Marketing, Inc.$301
- Mallinckrodt Hospital Products Inc.$298
- Travere Therapeutics, Inc.$206
- plus $507 from 8 others
Across 35 payments — averaging $13,942 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$309K
- CSL Behring$179K
What the payments were for
- Travel & lodging$2,08040%
- Food & beverage$3,07959%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 6 | $2,225 |
| Vifor Pharma, Inc. | 78 | $1,088 |
| Amgen(2 entities) | 46 | $570 |
| Fresenius USA Marketing, Inc. | 15 | $301 |
| Mallinckrodt Hospital Products Inc. | 11 | $298 |
| Travere Therapeutics, Inc. | 16 | $206 |
| Akebia Therapeutics Inc | 9 | $167 |
| AstraZeneca | 7 | $136 |
| GSK | 3 | $50 |
| Aurinia Pharma U.S., Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 3 | $40 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Bayer | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TERLIVAZ$122
How this compares
$5,196 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 79 | $195,802 |
| VeltassaPatiromer Calcium Sorbitex | 102 | $133,110 |
| AuryxiaFerric Citrate | 38 | $105,644 |
| Sevelamer Carbonate | 143 | $37,876 |
| LokelmaSodium Zirconium Cyclosilicate | 23 | $31,231 |
| FarxigaDapagliflozin Propanediol | 13 | $11,775 |
| Lanthanum Carbonate | 12 | $5,536 |
| Cinacalcet Hcl | 38 | $4,064 |
| Bumetanide | 36 | $2,127 |
| Nifedipine ErNifedipine | 34 | $1,973 |
| Calcium Acetate | 13 | $1,526 |
| Gentamicin Sulfate | 13 | $622 |
| Hydralazine Hcl | 37 | $403 |
| Tamsulosin Hcl | 28 | $358 |
| Losartan Potassium | 53 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $301 | $195,80279 claims |
| Akebia Therapeutics IncAuryxia | $167 | $105,64438 claims |
| AstraZenecaLokelma, Farxiga | $136 | $43,00636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in McAllen
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.